سعر مبيفيروباك 400مجم 28 قرص 2022

Mpiviropack 400 mg tablets (Marcyrl Co., Egypt): sofosbuvir, an HCV NS5B polymerase inhibitor used as part of combination regimens for chronic hepatitis C; pack of 28 tablets.

• Chronic hepatitis C genotype 1, 2, 3 or 4 in adults without cirrhosis or with compensated cirrhosis, as a component of a combination antiviral regimen.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Chronic hepatitis C genotype 2 or 3 in children 3 years and older (with ribavirin), per US label; weight-based dosing uses 400 mg or lower-strength forms.Population: Children 3 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse events (at least 20%) with sofosbuvir plus ribavirin: fatigue and headache; with peginterferon alfa/ribavirin, the profile also reflects those agents.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• When used with ribavirin or peginterferon alfa/ribavirin, all contraindications of those agents apply to the combination.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: risk of hepatitis B virus reactivation in HCV/HBV coinfected patients, sometimes causing fulminant hepatitis, hepatic failure and death; test all patients for current or prior HBV infection before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious symptomatic bradycardia, including a fatal cardiac arrest and cases requiring pacemaker, has been reported when amiodarone is co-administered with a sofosbuvir-containing regimen; risk higher with beta-blockers, cardiac comorbidities or advanced liver disease.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Intestinal P-gp inducers (e.g. rifampicin, St John's wort) may reduce sofosbuvir concentrations and effect; co-administration is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• AmiodaroneSerious symptomatic bradycardia when co-administered with sofosbuvir-containing regimens; avoid or monitor closely as directed by the label.DailyMed (U.S. National Library of Medicine)
• P-gp inducers (rifampicin, St John's wort and others)Decrease sofosbuvir plasma concentration and may reduce therapeutic effect; co-administration not recommended.DailyMed (U.S. National Library of Medicine)
• Antidiabetic medicines and warfarinClearance of HCV may change hepatic function; serious symptomatic hypoglycaemia has been reported in diabetic patients, so frequent monitoring of glucose (and INR for warfarin) is advised.DailyMed (U.S. National Library of Medicine)

• No adequate human data; no adverse developmental outcomes in animal studies at exposures above human exposure. If used with ribavirin (with or without peginterferon), the combination is contraindicated in pregnant women and in men whose female partners are pregnant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether sofosbuvir or its metabolites are present in human milk; the main metabolite GS-331007 was found in rat milk without effect on pups. Weigh breastfeeding benefits against maternal need; ribavirin information applies if co-administered.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Sofosbuvir: Nucleotide prodrug converted intracellularly to the active uridine analogue triphosphate (GS-461203), which is incorporated into HCV RNA by the NS5B RNA-dependent RNA polymerase and acts as a chain terminator (US label, section 12.4).